Changes

The FDA noted two flaws in the study. First, the sample size was very small. Second, the control group of fish were not farm-raised salmon. Also, instead of noting the "percent inhibition" (a numeric, quantitative measure of allergenicity), the study determined what it called "relative potency" as its measure of allergenicity, a term that the testing laboratory was unable to define when asked by the FDA. To correct for this, the FDA requested the raw data and used it in its analysis. Additionally, Michael Hansen notes, as an additional flaw, that the study was not a blind study.<ref>Jill Richardson, Phone interview with Michael Hansen, September 7, 2010.</ref>